{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:27Z","timestamp":1759104207927,"version":"3.44.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jneuroim.2023.578037","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T21:11:35Z","timestamp":1675113095000},"page":"578037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recurrent encephalopathy associated with pegylated beta-interferon treatment"],"prefix":"10.1016","volume":"376","author":[{"given":"Francisca","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Soares-dos-Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2000","series-title":"Managing the Adverse Effects of Interferon-\u03b2 Therapy in Multiple Sclerosis","author":"Bayas","key":"10.1016\/j.jneuroim.2023.578037_bb0005"},{"issue":"7","key":"10.1016\/j.jneuroim.2023.578037_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2023.578037_bb0015","series-title":"CNS Drugs","first-page":"743","article-title":"Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon Beta-1a (Avonex)","volume":"vol. 35, Issue 7","author":"Cohan","year":"2021"},{"issue":"1","key":"10.1016\/j.jneuroim.2023.578037_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02471-7","article-title":"Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation","volume":"21","author":"Dietz","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2023.578037_bb0025","series-title":"Cold Spring Harbor Perspectives in Medicine","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"vol. 8, Issue 11","author":"Jakimovski","year":"2018"},{"year":"2016","series-title":"Type I Interferon Causes Thrombotic Microangiopathy by a Dose-Dependent Toxic Effect on the Microvasculature","author":"Kavanagh","key":"10.1016\/j.jneuroim.2023.578037_bb0030"},{"key":"10.1016\/j.jneuroim.2023.578037_bb0035","article-title":"Posterior reversible encephalopathy syndrome, multiple sclerosis and interferon therapy: association, co-incidence or convoluted interplay?","volume":"45","author":"Mastorodemos","year":"2020","journal-title":"Multiple Scler. Relat. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:54Z","timestamp":1759048914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572823000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":7,"alternative-id":["S0165572823000231"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578037","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent encephalopathy associated with pegylated beta-interferon treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"578037"}}